Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References KesimptaⓇ accelerating launch momentum driving B-cell market growth Sales evolution USD m, % cc +65% 109 66 ◉ Q2 2021 Q3 2021 Solid launch execution in US Strong contributor to B-cell therapy market growth ■ NBRx share 12.7%1, 2nd highest ahead of AubagioⓇ and TecfideraⓇ ■ >6k patients treated, majority naive or first switch ■ +34% prescribers in the quarter Continuing clinical differentiation ■ ALITHIOS: IgG levels preserved over 3.5 years with low risk of serious infections ■ 94% COVID-19 cases mild / moderate in unvaccinated treated adults Ongoing / initiating studies include immune response to SARS-CoV-2 mRNA vaccines, efficacy and safety of switching from other therapies, investigating PROS in early RMS population in real-world setting IgG Immunoglobulin G PIRA - Progression independent of relapse activity PROS - Patient reported outcomes 1. Unadjusted exit share by end of Q3 30 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation